Biotechnology ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference May 16, 2022
Biotechnology Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs May 16, 2022
Biotechnology Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month May 16, 2022
Biotechnology SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AXSM May 15, 2022
Biotechnology Pomerantz Law Firm Announces the Filing of a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM May 13, 2022
Biotechnology FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. – FGEN May 13, 2022
Biotechnology Shareholder Alert – The M&A Class Action Firm Announces an Investigation of BioHaven Pharmaceutical Holding Company Ltd. – BHVN May 13, 2022
Search
biotech stock market
May 15, 2022
